RDHL Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 112332 min ago

@ $0.562

Wydano: 12 vas. 2024 @ 18:22

Zwrot: -22.94%

Poprzedni sygnał: vas. 7 - 18:41

Poprzedni sygnał: Sprzedaż

Zwrot: 4.13 %

Live Chart Being Loaded With Signals

Commentary (30 bal. 2024 @ 19:15):

Stats
Dzisiejszy wolumen	59 230.00
Średni wolumen	588 948
Kapitalizacja rynkowa	12.86M
EPS	$-22.40 ( 2024-03-10 )
Następna data zysków	( $0 ) 2024-06-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0.110
ATR14	$0.00200 (0.46%)

Wolumen Korelacja

Długi: -0.24 (neutral)

Krótki: 0.00 (neutral)

Signal:(45.934) Neutral

Redhill Biopharma Ltd Korelacja

10 Najbardziej pozytywne korelacje
TTCF	0.968
LNSR	0.963
VIRX	0.961
WISA	0.959
IMRX	0.957
NOTV	0.956
IMCC	0.955
SRZN	0.955
SNCE	0.954
FATE	0.95

10 Najbardziej negatywne korelacje
MGI	-0.956
CCRC	-0.944
PWOD	-0.942
STIM	-0.937
NWFL	-0.935
IMMR	-0.933
ROST	-0.93
HZNP	-0.929
ACAHU	-0.924
EWEB	-0.924

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Redhill Biopharma Ltd Korelacja - Waluta/Towar

0.29
( neutral )

0.38
( neutral )

0.00
( neutral )

-0.29
( neutral )

Redhill Biopharma Ltd Finanse

Annual	2023
Przychody:	$6.51M
Zysk brutto:	$3.06M (47.03 %)
EPS:	$3.68

FY	2023
Przychody:	$6.51M
Zysk brutto:	$3.06M (47.03 %)
EPS:	$3.68

FY	2023
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$0

FY	2022
Przychody:	$61.80M
Zysk brutto:	$28.46M (46.06 %)
EPS:	$-38.27

Financial Reports:

No articles found.

Redhill Biopharma Ltd

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.